MEDP

Medpace Holdings, Inc. NASDAQ

Healthcare ·Medical - Diagnostics & Research ·US · medpace.com

$417.02

Mkt Cap $11.9B

52w Low $284.10 38.5% of range 52w High $628.92

50d MA $467.28 200d MA $512.48

P/E (TTM) 26.7x

EV/EBITDA 28.0x

P/B 26.2x

Debt/Equity 0.6x

ROE 77.0%

P/FCF 23.8x

RSI (14) —

ATR (14) —

Beta 1.39

50d MA $467.28

200d MA $512.48

Avg Volume 428.4K

About

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and devel…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Apr 22, 2026	AMC	3.74	4.28	+14.4%	508.46	-26.2%	-22.6%	-19.3%	-17.1%	-19.4%	-18.7%	—
Feb 9, 2026	AMC	4.19	4.67	+11.5%	530.35	-7.8%	-15.9%	-20.1%	-21.6%	-19.3%	-19.3%	—
Oct 22, 2025	AMC	3.53	3.86	+9.3%	546.74	+13.3%	+9.1%	+10.7%	+9.1%	+6.2%	+6.9%	—
Jul 21, 2025	AMC	2.98	3.10	+4.0%	308.88	+44.3%	+54.7%	+41.6%	+47.5%	+44.9%	+46.7%	—
Apr 21, 2025	AMC	3.06	3.67	+19.9%	288.99	-10.3%	-2.3%	+0.5%	+4.8%	+3.3%	+3.2%	—
Feb 10, 2025	AMC	2.96	3.67	+24.0%	354.51	-3.9%	-7.5%	-5.1%	-3.4%	-4.0%	-3.9%	—
Oct 21, 2024	AMC	2.78	3.01	+8.3%	352.92	-13.6%	-7.5%	-6.5%	-7.0%	-6.4%	-6.7%	—
Jul 22, 2024	AMC	2.54	2.75	+8.3%	437.18	-17.5%	-18.3%	-12.6%	-13.0%	-12.7%	-11.9%	—
Apr 22, 2024	AMC	2.47	3.20	+29.6%	376.26	+0.5%	+8.2%	+5.7%	+3.6%	+5.2%	+6.4%	—
Feb 12, 2024	AMC	2.22	2.46	+10.8%	324.21	+0.8%	+12.3%	+20.2%	+21.6%	+20.8%	+18.5%	—
Oct 23, 2023	AMC	2.05	2.22	+8.3%	227.52	+9.9%	+19.7%	+13.6%	+12.5%	+10.0%	+6.3%	—
Jul 24, 2023	AMC	1.91	1.93	+1.0%	246.94	-6.9%	+3.9%	+3.9%	+0.8%	+3.2%	+2.5%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 24	Baird	Maintains	Outperform → Outperform	—	$393.42	$390.01	-0.9%	+4.4%	+7.1%	+4.1%	+5.1%	+6.4%
Apr 24	Barclays	Maintains	Equal Weight → Equal Weight	—	$393.42	$390.01	-0.9%	+4.4%	+7.1%	+4.1%	+5.1%	+6.4%
Apr 24	RBC Capital	Maintains	Outperform → Outperform	—	$393.42	$390.01	-0.9%	+4.4%	+7.1%	+4.1%	+5.1%	+6.4%
Apr 24	BMO Capital	Maintains	Market Perform → Market Perform	—	$393.42	$390.01	-0.9%	+4.4%	+7.1%	+4.1%	+5.1%	+6.4%
Mar 6	Barclays	Upgrade	Underweight → Equal Weight	—	$469.38	$469.50	+0.0%	+0.3%	+2.0%	-0.6%	+1.8%	-5.4%
Feb 18	TD Cowen	Upgrade	Sell → Hold	—	$428.18	$432.16	+0.9%	+4.2%	+4.3%	+6.0%	+3.9%	+3.3%
Feb 13	Jefferies	Upgrade	Hold → Buy	—	$416.04	$421.45	+1.3%	+2.9%	+2.9%	+7.2%	+7.3%	+9.1%
Feb 11	Barclays	Maintains	Underweight → Underweight	—	$446.05	$446.83	+0.2%	-5.0%	-6.7%	-4.0%	-4.0%	+0.0%
Feb 11	Truist	Maintains	Hold → Hold	—	$446.05	$446.83	+0.2%	-5.0%	-6.7%	-4.0%	-4.0%	+0.0%
Feb 11	Leerink Partners	Maintains	Market Perform → Market Perform	—	$446.05	$446.83	+0.2%	-5.0%	-6.7%	-4.0%	-4.0%	+0.0%
Dec 15	Barclays	Maintains	Underweight → Underweight	—	$557.90	$557.90	+0.0%	+0.2%	+0.2%	-0.1%	+0.4%	+1.9%
Oct 27	Truist	Maintains	Hold → Hold	—	$605.20	$606.59	+0.2%	-1.4%	-4.1%	-3.4%	-4.1%	-3.4%
Oct 24	Mizuho	Maintains	Outperform → Outperform	—	$596.61	$603.05	+1.1%	+1.4%	-0.0%	-2.7%	-2.0%	-2.7%
Oct 24	TD Cowen	Maintains	Sell → Sell	—	$596.61	$603.05	+1.1%	+1.4%	-0.0%	-2.7%	-2.0%	-2.7%
Oct 24	Barclays	Maintains	Underweight → Underweight	—	$596.61	$603.05	+1.1%	+1.4%	-0.0%	-2.7%	-2.0%	-2.7%
Oct 17	Mizuho	Maintains	Outperform → Outperform	—	$521.21	$520.49	-0.1%	+1.3%	+4.5%	+4.7%	+4.9%	+14.5%
Oct 2	Barclays	Downgrade	Equal Weight → Underweight	—	$543.90	$525.75	-3.3%	-1.4%	-2.1%	-2.5%	-2.2%	-2.4%
Sep 9	Jefferies	Maintains	Hold → Hold	—	$492.09	$491.37	-0.1%	-1.3%	-3.1%	+1.1%	-0.3%	+0.9%
Sep 3	Rothschild & Co	Downgrade	Buy → Neutral	—	$473.34	$468.09	-1.1%	+1.7%	+1.9%	+2.9%	+4.0%	+2.6%
Jul 29	UBS	Downgrade	Neutral → Sell	—	$453.05	$431.89	-4.7%	-1.1%	-3.4%	-5.7%	-6.6%	-4.6%
Jul 25	Mizuho	Maintains	Outperform → Outperform	—	$455.68	$445.00	-2.3%	-1.8%	-0.6%	-1.7%	-3.9%	-6.2%
Jul 23	Deutsche Bank	Maintains	Hold → Hold	—	$477.73	$470.70	-1.5%	-8.4%	-4.6%	-6.3%	-5.2%	-6.2%
Jul 23	TD Cowen	Downgrade	Hold → Sell	—	$477.73	$470.70	-1.5%	-8.4%	-4.6%	-6.3%	-5.2%	-6.2%
Jul 23	Barclays	Maintains	Equal Weight → Equal Weight	—	$477.73	$470.70	-1.5%	-8.4%	-4.6%	-6.3%	-5.2%	-6.2%
Jul 23	Baird	Maintains	Neutral → Neutral	—	$477.73	$470.70	-1.5%	-8.4%	-4.6%	-6.3%	-5.2%	-6.2%
Jul 23	Truist	Maintains	Hold → Hold	—	$477.73	$470.70	-1.5%	-8.4%	-4.6%	-6.3%	-5.2%	-6.2%
Apr 23	Baird	Maintains	Neutral → Neutral	—	$282.28	$293.42	+3.9%	+2.9%	+7.3%	+5.8%	+5.6%	+8.5%
Apr 23	Truist	Maintains	Hold → Hold	—	$282.28	$293.42	+3.9%	+2.9%	+7.3%	+5.8%	+5.6%	+8.5%
Apr 22	William Blair	Downgrade	Outperform → Market Perform	—	$288.99	$259.13	-10.3%	-2.3%	+0.5%	+4.8%	+3.3%	+3.2%
Apr 14	TD Cowen	Downgrade	Buy → Hold	—	$297.72	$298.42	+0.2%	+2.5%	+2.4%	-0.4%	-0.5%	-2.9%
Apr 10	Truist	Maintains	Hold → Hold	—	$302.56	$297.85	-1.6%	-6.7%	-1.6%	+0.9%	+0.8%	-2.0%
Apr 9	Mizuho	Maintains	Outperform → Outperform	—	$277.23	$274.58	-1.0%	+9.1%	+1.8%	+7.4%	+10.1%	+10.0%
Jan 27	Baird	Maintains	Neutral → Neutral	—	$344.07	$343.47	-0.2%	+1.8%	+0.5%	-0.3%	+1.7%	+1.5%
Nov 25	Baird	Maintains	Neutral → Neutral	—	$337.75	$341.65	+1.2%	+0.0%	-0.8%	+0.4%	+0.9%	+1.4%
Oct 23	TD Cowen	Maintains	Buy → Buy	—	$326.54	$326.49	-0.0%	+1.1%	+0.5%	+1.1%	+0.9%	+1.0%
Oct 23	Baird	Downgrade	Outperform → Neutral	—	$326.54	$326.49	-0.0%	+1.1%	+0.5%	+1.1%	+0.9%	+1.0%
Oct 14	Truist	Maintains	Hold → Hold	—	$347.91	$350.00	+0.6%	+1.6%	+1.5%	-0.4%	-1.4%	+2.4%
Sep 27	UBS	Downgrade	Buy → Neutral	—	$326.26	$322.09	-1.3%	+1.6%	+2.3%	+2.2%	+3.3%	+3.5%
Sep 25	Jefferies	Downgrade	Buy → Hold	—	$355.82	$346.07	-2.7%	-9.9%	-8.3%	-6.9%	-6.2%	-6.3%
Sep 20	Baird	Maintains	Outperform → Outperform	—	$369.18	$367.98	-0.3%	-0.9%	-2.0%	-3.6%	-13.2%	-11.6%
Jul 24	TD Cowen	Maintains	Buy → Buy	—	$357.30	$357.30	+0.0%	+6.9%	+6.5%	+6.8%	+7.8%	+5.9%
Jul 24	Deutsche Bank	Maintains	Hold → Hold	—	$357.30	$357.30	+0.0%	+6.9%	+6.5%	+6.8%	+7.8%	+5.9%
Jul 24	Guggenheim	Maintains	Buy → Buy	—	$357.30	$357.30	+0.0%	+6.9%	+6.5%	+6.8%	+7.8%	+5.9%
Jul 24	Baird	Maintains	Outperform → Outperform	—	$357.30	$357.30	+0.0%	+6.9%	+6.5%	+6.8%	+7.8%	+5.9%
Jul 8	Baird	Maintains	Outperform → Outperform	—	$402.40	$404.75	+0.6%	+0.8%	+2.1%	+4.1%	+8.1%	+10.1%
Apr 24	Guggenheim	Maintains	Buy → Buy	—	$407.15	$415.00	+1.9%	-2.4%	-4.3%	-2.8%	-1.7%	-4.6%
Apr 24	Baird	Maintains	Outperform → Outperform	—	$407.15	$415.00	+1.9%	-2.4%	-4.3%	-2.8%	-1.7%	-4.6%
Apr 23	Jefferies	Upgrade	Hold → Buy	—	$376.26	$378.00	+0.5%	+8.2%	+5.7%	+3.6%	+5.2%	+6.4%
Mar 8	UBS	Maintains	Buy → Buy	—	$409.63	$413.40	+0.9%	-1.0%	-1.5%	-0.5%	-0.4%	-1.2%
Feb 15	UBS	Upgrade	Neutral → Buy	—	$389.80	$390.00	+0.1%	+1.2%	+0.5%	-1.5%	-0.9%	+1.0%

Recent Filings

8-K · 5.02 !!! Very High

Medpace Holdings, Inc. -- 8-K 5.02: Executive Change

Jesse Geiger's resignation as President of Medpace Holdings, effective May 31, 2026, signals upcoming leadership transition that investors should monitor for potential operational strategy changes and successor announcement.

Apr 22

8-K

Medpace Holdings, Inc. -- 8-K Filing

Medpace Holdings achieved strong 32% revenue growth in Q4 2025 to $708.5 million, demonstrating robust business momentum and effective backlog conversion at a 23.6% rate.

Feb 9

Data updated apr 26, 2026 11:47am · Source: massive.com